Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: Prolonged survival and preservation of cognitive function

Journal of Clinical Oncology

Volumn 9, Issue 9, 1991, Pages 1580-1590

  Neuwelt, Edward A ^a   Goldman, David L ^b   Dahlborg, Suellen A ^b   Crossen, John ^b   Ramsey, Fred ^b   Roman Goldstein, Simon ^b   Braziel, Rita ^b   Dana, Bruce ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FOLINIC ACID; MANNITOL; METHOTREXATE; PROCARBAZINE;

ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN CANCER; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SEIZURE; SURVIVAL; THROMBOSIS; TOXICITY;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; COGNITION; COMPARATIVE STUDY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FEMALE; HUMAN; LEUCOVORIN; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGE; NEUROPSYCHOLOGICAL TESTS; PROCARBAZINE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; SURVIVAL RATE;

EID: 0025866115     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1991.9.9.1580     Document Type: Article

References (74)

1. Gumerlock MK: Recognition and management of central nervous system lymphoma. Contemp Neurosurg 12:1-8, 1990
2. Eby NL, Grufferman S, Flannelly CM, et al: Increasing incidence of primary brain lymphoma in the U.S. Cancer 62:2461-2465, 1988
3. Greig NH, Ries LG, Yancik R, et al: Increasing annual incidence of primary malignant brain tumors in the elderly. J Natl Cancer Inst 82:1621-1624, 1990
4. Henry JM, Heffner RR Jr, Dillard SH, et al: Primary malignant lymphoma of the central nervous system. Cancer 34:1293-1302, 1974
5. Hochberg FH, Miller DC: Primary central nervous system lymphoma. J Neurosurg 68:835-853, 1988
6. Habeshaw JA, Lauder I: Malignant Lymphomas. New York, NY, Churchill Livingstone, 1988
7. Dana BW, Dahlberg S, Miller TP, et al: m-BACOD treatment for intermediate- and high-grade malignant lymphomas: A Southwest Oncology Group phase II trial. J Clin Oncol 8:1155-1162, 1990
8. Berry MP, Simpson WJ: Radiation therapy in the management of primary malignant lymphoma of the brain. Int J Radiat Oncol Biol Phys 7:55-59, 1981
9. Letendre L, Banks PM, Reese DF, et al: Primary lymphoma of the central nervous system. Cancer 49:939-943, 1982
10. Mendenhall NP, Thar TL, Agee OF, et al: Primary lymphoma of the central nervous system. Cancer 52:1993-2000, 1983
11. Stewart DJ, Russell N, Atack EA: Cyclophosphamide, Adriamycin, vincristine, and dexamethasone in the treatment of bulky central nervous system lymphoma, in Walker MD, Thomas DGT, (eds): Biology of Brain Tumors. Boston, MA, Martinus-Nijoff, 1986, p 433-436
12. Hawkey CJ, Toghill PJ: The need for prophylactic treatment to the central nervous system in patients with aggressive non-Hodgkins lymphoma. Postgrad Med J 59:283-287, 1983
13. Neuwelt EA: Implications of the Blood-Brain Barrier and its Manipulation: Clinical Implications, Vol 2. New York, NY, Plenum, 1989
14. Abelson HT, Kufe DW, Skarin AT: Treatment of central nervous system tumors with methotrexate. Cancer Treat Rep 65:137-140, 1981
15. Ervin T, Canellos GP: Successful treatment of recurrent primary central nervous system lymphoma with high-dose methotrexate. Cancer 45:1556-1557, 1980
16. Herbst KD, Corder MP, Justice GR: Successful therapy with methotrexate of a multicentric mixed lymphoma of the central nervous system. Cancer 38:1476-1478, 1976
17. Pitman SW, Frei E III: Weekly methotrexate, calcium leucovorin rescue: Effects of alkalinization on nephrotoxicity; pharmacokinetics in the CNS; and the use in CNS non-Hodgkins lymphoma. Cancer Treat Rep 61:695-701, 1977
18. Skarin AT, Zuckerman KS, Pitman SW, et al: High-dose methotrexate with folinic acid in the treatment of advanced non-Hodgkin lymphoma including CNS involvement. Blood 50:1039-1047, 1977
19. Shapiro WR, Young DG, Mehta B: Methotrexate distribution in cerebrospinal fluid after intravenous, ventricular, and lumbar injections. N Engl J Med 293:161-163, 1975
20. Djerassi I, Kim JS, Reggey A: Response of astrocytoma to high-dose methotrexate with citrovorum rescue. Cancer 55:2741-2747, 1985
21. Djerassi I, Kim JS, Shulman K: High-dose methotrexate-citrovorum factor rescue in the management of brain tumors. Cancer Treat Rep 61:691-694, 1988
22. Rosen G, Ghavimi F, Nirenberg A, et al: High-dose methotrexate with citrovorum factor rescue for the treatment of central nervous system tumors in children. Cancer Treat Rep 61:681-690, 1977
23. Kimelberg HK, Kung D, Watson RE, et al: Direct administration of methotrexate into the central nervous system of primates. Part I: Distribution and degradation of methotrexate in nervous and systemic tissue after intraventricular injection. J Neurosurg 48:883-894, 1978
24. Blasberg RG, Patlak C, Fenstermacher JD: Intrathecal chemotherapy: Brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Ther 195:73-83, 1985
25. Neuwelt EA, Frenkel E, D'Agostino AN: Growth of human lung tumor in the brain of the nude rat as a model to evaluate antitumor agent delivery across the blood-brain barrier. Cancer Res 45:2827-2833, 1985
26. 3H]Methotrexate loss from the rat brain following enhanced uptake by osmotic opening of the blood-brain barrier. Cancer Res 45:1092-1096, 1985
27. Rapoport SI: Effect of concentrated solutions on blood-brain barrier. Am J Physiol 219:270-274, 1970
28. Rapoport SI: Blood-brain barrier in Physiology and Medicine. New York, NY, Raven, 1976
29. Rapoport SI, Matthews K, Thompson HK, et al: Osmotic opening of the blood-brain barrier in the rhesus monkey without measurable brain edema. Brain Res 136:23-29, 1977
30. Neuwelt EA, Glasberg M, Diehl J: Osmotic blood-brain barrier disruption in posterior fossa of the dog. J Neurosurg 55:742-748, 1981
31. Neuwelt EA, Barnett PA, Glasberg M: Pharmacology and neurotoxicity of cis-diamminedichloroplatinum, bleomycin, 5-fluorouracil, and cyclophosphamide administration following osmotic blood-brain barrier modification. Cancer Res 43:5278-5285, 1983
32. Neuwelt EA, Glasberg M, Frenkel E: Neurotoxicity of chemotherapeutic agents after blood-brain barrier modification: Neuropathological studies. Ann Neurol 14:316-324, 1983
33. Neuwelt EA, Frenkel EP, Gumerlock MK: Developments in the diagnosis and treatment of primary CNS lymphoma: A prospective series. Cancer 58:1609-1620, 1986
34. Neuwelt EA, Hill S, Rapoport S, et al: Delivery of therapeutic levels of methotrexate to the brain after reversible disruption of the blood-brain barrier. Proc Am Assoc Cancer Res 20:99, 1979 (abstr)
35. Neuwelt EA, Diehl JT, Long H, et al: Monitoring of methotrexate delivery in patients with malignant brain tumors after osmotic blood-brain barrier disruption. Ann Intern Med 94:449-454, 1981
36. Grieco A, Long CJ: Investigation of the Karnofsky performance status as a measure of quality of life. Health Psychol 3:129-142, 1984
37. Coscarelli-Schag C, Heinrich FL, Ganz PA: Karnofsky performance status revisited: Reliability, validity, and guidelines. J Clin Oncol 2:187-192, 1984
38. Wientraub S, Mesulam MM: Mental state assessment of young and elderly adults in behavioral neurology, in Mesulam MM (ed): Principles of Behavioral Neurology. Philadelphia, PA, F.A. Davis, 1985, pp 71-123
39. Littman P, Wang CC: Reticulum cell carcinoma of the brain: A review of the literature and a study of 19 cases. Cancer 35:1412-1420, 1975
40. Sagerman RH, Collier CH, King GA: Radiation therapy of microgliomas. Radiology 149:567-570, 1983
41. Woodman R, Shin K, Pineo G: Primary non-Hodgkin's lymphoma of the brain. A review. Medicine 64:425-430, 1985
42. Gonzalez DG, Schuster-Uitterhoeve ALJ: Primary non-Hodgkin's lymphoma of the central nervous system. Results of radiotherapy in 15 cases. Cancer 51:2048-2052, 1983
43. Helle TL, Britt RH, Colby TV: Primary lymphoma of the central nervous system. Clinicopathological study of experience at Stanford. J Neurosurg 60:94-103, 1984
44. Rampen FHJ, van Andel JG, Sizoo W, et al: Radiation therapy in primary non-Hodgkin's lymphomas of the CNS. Eur J Cancer 16:177-184, 1980
45. Freeman CR, Shustik CH, Brisson M-L, et al: Primary malignant lymphoma of the central nervous system. Cancer 58:1106-1111, 1986
46. Yasunaga T, Takahashi M, Uozumi H, et al: Radiation therapy of primary malignant lymphoma of the brain. Acta Radiologica Oncol 25:23-28, 1986
47. Hobson DE, Anderson BA, Carr I, et al: Primary lymphoma of the central nervous system: Manitoba experience and literature review. Can J Neurol Sci 13:55-61, 1986
48. Ashby MA, Bowen D, Bleehen NM, et al: Primary lymphoma of the central nervous system: Experience at Addenbrooke's Hospital, Cambridge. Clin Radiol 39:173-181, 1988
49. Vakili ST, Muller J, Shidnia H, et al: Primary lymphoma of the central nervous system: A clinicopathologic analysis of 26 cases. J Surg Oncol 33:95-102, 1986
50. Frank G, Ferracini R, Spagnolli F, et al: Primary intracranial lymphomas. Surg Neurol 23:3-8, 1985
51. Kawakami Y, Tabuchi K, Ohnishi R, et al: Primary central nervous system lymphoma. J Neurosurg 62:522-527, 1985
52. Sokol RR, RolifT FJ: Biometry, ed 2. New York, NY, WH Freeman and Co, 1980
53. Lawless JF: Statistical Models and Methods for Life-time Data. New York, NY, Wiley, 1982
54. Cox DR: Regression models and life tables. J R Stat Soc (B) 34:187-220, 1972
55. Pollack IF, Lunsford LD, Flickinger JC, et al: Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 63:939-947, 1989
56. Michalski JM, Garcia DM, Kase E: Primary central nervous system lymphoma: Analysis of prognostic variables and patterns of treatment failure. Radiology 176:855-860, 1990
57. Millay RH, Shults WT, Neuwelt EA, et al: Maculopathy associated with combination chemotherapy and osmotic blood-brain barrier opening. Am J Ophthalmol 102:626-632, 1986
58. Sage MR, Turski PA, Levin A: CNS imaging and the brain interfaces, in Neuwelt EA (ed): Implications of the Blood-Brain Barrier and Its Manipulation, Clinical Implications, vol 2. New York, NY, Plenum, 1989, pp 1-51
59. Groothuis DR, Warkne PC, Molnar P, et al: Effect of hyperosmotic blood-brain barrier disruption on transcapillary transport in canine brain tumors. J Neurosurg 72:441-449, 1990
60. Warnke PC, Blasberg RG, Groothuis DR: The effect of hyperosmotic blood-brain barrier disruption on blood-to-tissue transport in ENU-induced gliomas. Ann Neurol 22:300-305, 1987
61. Fishman RA: Is there a role for osmotic breaching of the blood-brain barrier? Ann Neurol 22:298-299, 1987
62. Nakagawa H, Groothuis D, Blasberg RG: The effect of graded hypertonic intracarotid infusions on drug delivery to experimental RG-2 gliomas. Neurology 34:1571-1581, 1984
63. Rapoport SI: Osmotic opening of the blood-brain barrier. Ann Neurol 24:677-684, 1988
64. Neuwelt EA, Barnett PA, Bigner DD, et al: Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: The factor of the blood-brain barrier. Proc Natl Acad Sci (USA) 79:4420-4423, 1982
65. Blasberg RG, Groothuis D, Molnar P: A review of hyperosmotic blood-brain barrier disruption in seven experimental brain tumor models, in Johansson BB, Widner COH (eds): Pathophysiology of the Blood-Brain Barrier. New York, NY, Elsevier, 1990, pp 197-220
66. Neuwelt EA, Frenkel EP, Gumerlock MK, et al: Developments in the diagnosis and treatment of primary CNS lymphoma: A prospective series. Cancer 58:1609-1620, 1986
67. Hill BT, Shellard SA, Hosking LK, et al: Enhanced DNA repair and tolerance of DNA damage associated with resistance to cis-diammine-dichloroplatinum (II) after in vitro exposure of a human teratoma cell line to fractionated x-irradiation. Int J Radiat Oncol Biol Phys 19:75-83, 1990
68. Loeffler JS, Ervin TJ, Mauch P, et al: Primary lymphomas of the central nervous system: Patterns of failure and factors that influence survival. J Clin Oncol 3:490-494, 1985
69. O'Neill BP, Illig JJ: Primary central nervous system lymphoma. Mayo Clin Proc 64:1005-1020, 1989
70. Gabbai AA, Hochberg FH, Linggood RM, et al: High-dose methotrexate for non-AIDS primary central nervous system lymphoma. J Neurosurg 70:190-194, 1989
71. DeAngelis LM, Yahalom J, Heinemann M-H: Primary CNS lymphoma: Combined treatment with chemotherapy and radiotherapy. Neurology 40:80-86, 1990
72. Chamberlain MC. Levin VA: Adjuvant chemotherapy for primary lymphoma of the central nervous system. Arch Neurol 47:1113-1116, 1990
73. Johnson BE, Becker B, Goff WB, et al: Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small-cell lung cancer. J Clin Oncol 3:1659-1667, 1985
74. Johnson BE, Patronas N, Hayes W, et al: Neurologic, computed cranial tomographic, and magnetic resonance imaging abnormalities in patients with small-cell lung cancer. Further follow-up of 6- to 13-year survivors. J Clin Oncol 8:48-56, 1990